Keros Therapeutics, Inc. (KROS) — DEFA14A Filings
All DEFA14A filings from Keros Therapeutics, Inc.. Browse 3 DEFA14A reports with AI-powered summaries and risk analysis.
DEFA14A Filings (3)
-
Keros Therapeutics Files Proxy Statement with Glass Lewis Recommendation
— May 27, 2025 Risk: low
Keros Therapeutics, Inc. filed a DEFA14A proxy statement on May 27, 2025, which includes a press release announcing a recommendation from Glass Lewis & Co. The -
Keros Therapeutics Files Proxy Statement Supplement
— May 19, 2025 Risk: low
Keros Therapeutics, Inc. filed a Definitive Additional Materials filing (DEFA14A) on May 19, 2025, as a supplement to its Proxy Statement for the 2025 Annual Me -
Keros Therapeutics Proxy Fight: Stockholder Withholds Votes
— May 9, 2025 Risk: medium
Keros Therapeutics, Inc. filed a DEFA14A proxy statement on May 9, 2025, related to a stockholder's announcement to withhold votes from two director nominees, M
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX